SET domain containing 4Genealiases: C21orf18 · C21orf27
Q-omics provides the consensus-scored SETD4 profile across patient tissues and cancer cell-line models. SETD4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SETD4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SETD4 RNA expression shows 20,749 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where SETD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETD4 survival associations across molecular data types. SETD4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETD4 RNA expression–survival associations across cancer types. High SETD4 expression shows unfavorable associations in KIRC, UVM, ACC, LIHC and PRAD, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SETD4 RNA expression.
This table summarizes SETD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SETD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETD4 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, BLCA, HNSC and CHOL. The COAD box plot shows higher SETD4 RNA expression in tumor versus normal tissue (log2 FC = +0.520, t-test p < 0.001).
This table shows molecular features associated with SETD4 in patient tissues and cancer cell lines. In patient samples, SETD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SETD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
